Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.
Conaghan P, Cohen S, Burmester G, Mysler E, Nash P, Tanaka Y, Rigby W, Patel J, Shaw T, Betts KA, Patel P, Liu J, Sun R, Fleischmann R.
Conaghan P, et al. Among authors: fleischmann r.
Rheumatol Ther. 2022 Feb;9(1):191-206. doi: 10.1007/s40744-021-00399-5. Epub 2021 Nov 23.
Rheumatol Ther. 2022.
PMID: 34816388
Free PMC article.